Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore

You may also be interested in...

Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China

The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.

Singapore’s Clinical Trials Registry May Attract Wider Patient Pool

The launch of a clinical trials registry in Singapore is another step in the wealthy city-state’s efforts to serve as a treatment hub in Asia for cutting-edge therapies.

South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub

Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts